Search Results - "Herrmann, Franziska Elena"

BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis by Herrmann, Franziska Elena, Hesslinger, Christian, Wollin, Lutz, Nickolaus, Peter

“…The anti-inflammatory and immunomodulatory abilities of oral selective phosphodiesterase 4 (PDE4) inhibitors enabled the approval of roflumilast and apremilast…”
Get full text

Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis by Herrmann, Franziska Elena, Hesslinger, Christian, Wollin, Lutz, Nickolaus, Peter

“…[This corrects the article DOI: 10.3389/fphar.2022.838449.]…”
Get full text

PDE4B inhibition by nerandomilast: Effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells by Reininger, Dennis, Fundel‐Clemens, Katrin, Mayr, Christoph H., Wollin, Lutz, Laemmle, Baerbel, Quast, Karsten, Nickolaus, Peter, Herrmann, Franziska Elena

“…Background and Purpose The PDE4 family is considered a prime target for therapeutic intervention in several fibro‐inflammatory diseases. We have investigated…”
Get full text

Olodaterol shows anti‐fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis by Herrmann, Franziska Elena, Wollin, Lutz, Wirth, Johannes, Gantner, Florian, Lämmle, Bärbel, Wex, Eva

“…Background and Purpose Idiopathic pulmonary fibrosis (IPF) is a fatal respiratory disease characterized by excessive fibroblast activation ultimately leading…”
Get full text

Tyrosine kinase inhibitor BIBF1000 does not hamper right ventricular pressure adaptation in rats by de Raaf, Michiel Alexander, Herrmann, Franziska Elena, Schalij, Ingrid, de Man, Frances S, Vonk-Noordegraaf, Anton, Guignabert, Christophe, Wollin, Lutz, Bogaard, Harm Jan

“…BIBF1000 is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR),…”
Get more information